Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023
/PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies...
United States Chunlei Li Valerie Malyvanh Jansen Yakun Wang Elevation Oncology Inc Corporate Communications Investor Relations
Source: prnewswire.com